Gilead CEO Martin to Step Down, Will Be Replaced by COO

  • Martin presided over strategy to acquire, develop hep C drug
  • Under Martin, company went from tiny biotech to giant

Gilead Sciences Inc. Chief Executive Officer John Martin, under whom the company developed one of the fastest-selling drugs of all time, will step down and be replaced by Chief Operating Officer John Milligan.

To continue reading this article you must be a Bloomberg Professional Service Subscriber.